Enter Note Done
Go to previous page in this tab
Session
  • Presentation | Esophageal, Gastric & Duodenal Disorders (EGD) Section Distinguished Abstract Plenary
  • AGA
  • Share Icon
  • 793: THE EFFICACY AND SAFETY OF RIFASUTENIZOLE (TNP-2198) BASED TRIPLE REGIMEN AS FIRST-LINE THERAPY FOR HELICOBACTER PYLORI INFECTION: A MULTICENTER, DOUBLE-BLIND, RANDOMIZED, CONTROLLED, PHASE 3 TRIAL
  • Session Number: 0006
    Set Timezone

Presentation ID: 793

4232467

Society
Main Session